Search Results for: CLINICAL TRIALS Why Are Metrics
Craig Morgan believes metrics are indeed critical to efforts to rein in clinical trials that are either poorly initiated or have incurred unforeseen events, which place the original timelines and/or budgets at risk of overages.
Kai Langel believes the remote research model and purpose-built technology offer the tools and the right process to help modernize clinical research and bring it closer to the high standard set by today’s consumer technologies.
Craig Morgan says as clinical trials continue to evolve, drug companies will no longer be able to rely on existing, tried-and-tested manual methods or point solutions for success. And technology integration in the eClinical stack is not sufficient to bring about the step change in productivity that has to happen.
CLINICAL TRIALS – Outsourcing Early-Stage Clinical Trials: How to Mitigate Costs & Risk June 3, 2014
Roundtable Discussion: Contributor Cindy H. Dubin gathered leading CROs together to discuss the benefits of outsourcing early-stage clinical trials, how to mitigate the risks, and lower costs in the process.
EXECUTIVE INTERVIEW – Metrics Inc.: Poised for Growth in Contract, Proprietary & Generic Pharmaceuticals December 31, 2012
Phil Hodges, who will continue to serve as President of Metrics, talks about how he will guide the company’s future direction and growth, and what the recent transaction means for Metrics, Mayne, and their customers.
GENE & CELL THERAPY – Its Growing Potential to Disrupt Drug Research & Healthcare Delivery October 2, 2017
Jeff Galvin believes as the pace of gene and cell therapies accelerates over this next decade, potential cures for chronic diseases, cancer cures, and autosomal defect cures will result, and the efficacy of new therapeutics may move as much as $500 billion from traditional pharmaceuticals to gene technologies.
SPECIAL FEATURE – Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise April 2, 2014
Contributor Cindy H. Dubin asked leading CMOs and CDMOs to describe the value-added services they offer with respect to formulation and manufacturing. Solving challenges of insufficient solubility, poor stability, identifying excipient candidates, and particle design topped their list of offerings.